SCHEMBL7180900

SCHEMBL7180900

COc1ccc(PC(=O)c2c(C)cccc2C)c(C)c1.[LiH]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
FLT3 P36888 1/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
HTT P42858 1/20 0.38
RAB9A P51151 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
NPC1 O15118 1/20 0.38
ALDH1A1 P00352 4/20 0.37
MAPK1 P28482 2/20 0.37
PARP1 P09874 1/20 0.37
CYP3A4 P08684 1/20 0.37
HPGD P15428 1/20 0.37
LMNA P02545 1/20 0.37
S1PR4 O95977 1/20 0.37
MAPT P10636 1/20 0.37
ATM Q13315 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7174928 0.91 MAPT (0.39) MEN1KMT2AGAAFLT3RAB9A
SCHEMBL7188541 0.89 KMT2A (0.45) MEN1KMT2AGAAFLT3HTT
SCHEMBL7180005 0.89 MAPT (0.47) MEN1KMT2AGAACES2CES1
SCHEMBL7189833 0.89 MAPT (0.41) MEN1KMT2AGAAFLT3CES2
SCHEMBL7184548 0.88 ALDH1A1 (0.39) MEN1KMT2AGAAFLT3HTT
Lithium SCHEMBL7188548 0.86 KMT2A (0.45) MEN1KMT2AGAAHTTRAB9A
SCHEMBL7186834 0.86 ALDH1A1 (0.39) MEN1KMT2AGAAHTTALDH1A1
SCHEMBL7182777 0.85 ATM (0.32) ATM
SCHEMBL7182351 0.85 KMT2A (0.46) MEN1KMT2ARAB9ANPC1MAPK1
SCHEMBL7177209 0.85 SMN1; SMN2 (0.41) KMT2AGAAL3MBTL1ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MEN1 2312/4885KMT2A 1586/4885GAA 4753/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MEN1 2263/4885KMT2A 956/4885GAA 4793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.